International Drug Safety Monitoring
In the 1960s, following the Thalidomide Disaster, the World Health Organization (WHO) initiated the development of an international drug safety monitoring programme. The objectives of this WHO programme are to improve the quality and safety of pharmaceuticals, and to support public health programmes...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2019-09-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/151 |
| _version_ | 1797224627237289984 |
|---|---|
| author | A. S. Kazakov E. V. Shubnikova M. A. Darmostukova I. I. Snegireva G. V. Kutekhova K. E. Zatolochina N. Yu. Velts D. A. Kaperko Yu. V. Olefir |
| author_facet | A. S. Kazakov E. V. Shubnikova M. A. Darmostukova I. I. Snegireva G. V. Kutekhova K. E. Zatolochina N. Yu. Velts D. A. Kaperko Yu. V. Olefir |
| author_sort | A. S. Kazakov |
| collection | DOAJ |
| description | In the 1960s, following the Thalidomide Disaster, the World Health Organization (WHO) initiated the development of an international drug safety monitoring programme. The objectives of this WHO programme are to improve the quality and safety of pharmaceuticals, and to support public health programmes by providing information for effective assessment of the risk-benefit ratio of medicinal products. The paper outlines the main focus areas of the programme and the mechanism of interaction between the countries involved. It summarises the functions of the WHO Collaborating Centre for International Drug Monitoring located in Uppsala, namely, accumulation and assessment of data on efficacy, inefficacy and risks of medicinal products, which are communicated by the participating countries, and provision of reliable and coherent data to specialists. The paper provides a review of online resources and methods used by VigiBase — global database of adverse drug reactions — that make it possible to search and analyse the data statistically. It describes the functions of the national monitoring centres located in different regions, and their interaction with the WHO. The dissemination of objective and reliable medical information throughout the world, promotion of pharmacovigilance as a science, creation of international partnerships and pooling of expertise from different countries allow for a significant improvement in the safety of pharmacotherapy. |
| first_indexed | 2024-03-08T22:27:41Z |
| format | Article |
| id | doaj.art-b6d8dc91215348808819a2a332b5cf2d |
| institution | Directory Open Access Journal |
| issn | 2312-7821 2619-1164 |
| language | Russian |
| last_indexed | 2024-04-24T13:56:07Z |
| publishDate | 2019-09-01 |
| publisher | Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Безопасность и риск фармакотерапии |
| spelling | doaj.art-b6d8dc91215348808819a2a332b5cf2d2024-04-03T17:56:36ZrusMinistry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Безопасность и риск фармакотерапии2312-78212619-11642019-09-017312012610.30895/2312-7821-2019-7-3-120-126146International Drug Safety MonitoringA. S. Kazakov0E. V. Shubnikova1M. A. Darmostukova2I. I. Snegireva3G. V. Kutekhova4K. E. Zatolochina5N. Yu. Velts6D. A. Kaperko7Yu. V. Olefir8Peoples' Friendship University of Russia, Scientifi c Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsPeoples' Friendship University of RussiaScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsIn the 1960s, following the Thalidomide Disaster, the World Health Organization (WHO) initiated the development of an international drug safety monitoring programme. The objectives of this WHO programme are to improve the quality and safety of pharmaceuticals, and to support public health programmes by providing information for effective assessment of the risk-benefit ratio of medicinal products. The paper outlines the main focus areas of the programme and the mechanism of interaction between the countries involved. It summarises the functions of the WHO Collaborating Centre for International Drug Monitoring located in Uppsala, namely, accumulation and assessment of data on efficacy, inefficacy and risks of medicinal products, which are communicated by the participating countries, and provision of reliable and coherent data to specialists. The paper provides a review of online resources and methods used by VigiBase — global database of adverse drug reactions — that make it possible to search and analyse the data statistically. It describes the functions of the national monitoring centres located in different regions, and their interaction with the WHO. The dissemination of objective and reliable medical information throughout the world, promotion of pharmacovigilance as a science, creation of international partnerships and pooling of expertise from different countries allow for a significant improvement in the safety of pharmacotherapy.https://www.risksafety.ru/jour/article/view/151drug safety monitoringadverse drug reactionspharmacovigilanceworld health organizationvigibase |
| spellingShingle | A. S. Kazakov E. V. Shubnikova M. A. Darmostukova I. I. Snegireva G. V. Kutekhova K. E. Zatolochina N. Yu. Velts D. A. Kaperko Yu. V. Olefir International Drug Safety Monitoring Безопасность и риск фармакотерапии drug safety monitoring adverse drug reactions pharmacovigilance world health organization vigibase |
| title | International Drug Safety Monitoring |
| title_full | International Drug Safety Monitoring |
| title_fullStr | International Drug Safety Monitoring |
| title_full_unstemmed | International Drug Safety Monitoring |
| title_short | International Drug Safety Monitoring |
| title_sort | international drug safety monitoring |
| topic | drug safety monitoring adverse drug reactions pharmacovigilance world health organization vigibase |
| url | https://www.risksafety.ru/jour/article/view/151 |
| work_keys_str_mv | AT askazakov internationaldrugsafetymonitoring AT evshubnikova internationaldrugsafetymonitoring AT madarmostukova internationaldrugsafetymonitoring AT iisnegireva internationaldrugsafetymonitoring AT gvkutekhova internationaldrugsafetymonitoring AT kezatolochina internationaldrugsafetymonitoring AT nyuvelts internationaldrugsafetymonitoring AT dakaperko internationaldrugsafetymonitoring AT yuvolefir internationaldrugsafetymonitoring |